Bioequivalence of Rosiglitazone Tartrate Tables and Rosiglitazone Maleate Tables in Healthy Volunteers

SUN Pei-hong,ZHAO Xia,LIU Yu-wang,ZHONG Da-fang,WANG Wen-sheng,SUN Bing-hui,ZHOU Ying,CUI Yi-min
DOI: https://doi.org/10.3321/j.issn:1003-3734.2009.17.014
2009-01-01
Abstract:Objective:To evaluate the relative bioavailability and bioequivalence of rosiglitazone tartrate tables and rosiglitazone maleate tables in healthy volunteers.Methods: Single oral doses(4 mg) of rosiglitazone tartrate tables and rosiglitazone maleate tables were respectively administered to 20 healthy male volunteers in randomized crossover study.LC-MS/MS assay was applied to determine the concentration of rosiglitazone in serum.Results: The pharmacokinetic parameters after single oral doses of 4 mg rosiglitazone tartrate tables and rosiglitazone maleate tables were as follows: Tmax(0.61±0.29) and(0.72±0.37)h;Cmax(487±134) and(487±156) μg·mL-1;t1/2(4.33±1.00) and(4.43±0.98) h;AUC0-t(2 256±822) and(2 261±902) μg·h·mL-1;AUC0-∞(2 309±870) and(2 318±951) μg·h·mL-1.There were no significant differences between the parameters of 2 tablets.Conclusion: The concentration-time curve of rosiglitazone fitted to a two-compartment pharmacokinetic model.The relative bioavailability of single oral administration is(102.3±17.5)%.The two preparations are of bioequivalence.
What problem does this paper attempt to address?